One Shot to Rewrite Your DNA: The Race for the First In Vivo CRISPR Approval

The Data That Started the Sprint

Intellia's confidence isn't coming out of nowhere. Phase 2 data for lonvo-z were remarkable: a 96% reduction in monthly HAE attack rates, with 97% of patients remaining completely attack-free for up to three years.

HAE is a genetic condition that causes sudden, severe swelling episodes. These attacks can hit the face, limbs, or (most dangerously) the airway. Current treatments are chronic preventive therapies; patients take them indefinitely to keep attacks at bay. Lonvo-z aims to replace all of that with a single treatment that fixes the genetic root cause.

The HAELO Phase 3 trial tested whether that Phase 2 magic translates at scale, across a global patient population. Intellia clearly liked what they saw, because the FDA filing timeline is aggressive: submission in H2 2026, potential approval and launch in H1 2027.

Wall Street Is Cautiously Optimistic

Analysts have been watching Intellia with a mix of excitement and wariness. The stock (NTLA) trades around $13.63 to $14.40. Analyst price targets for NTLA range from a high of $106 to a low of $7. That spread tells you something: people agree this technology is transformative but disagree wildly on whether Intellia can execute.

The caution isn't unfounded. Intellia's other major program, nexiguran ziclumeran (nex-z) for transthyretin amyloidosis (a disease where misfolded proteins damage the heart and nerves), hit turbulence in late 2025. The FDA placed clinical holds on both Phase 3 trials after a patient developed severe liver enzyme elevations. One patient died. The clinical hold on MAGNITUDE-2 was lifted in January 2026 after Intellia added enhanced liver monitoring, and the MAGNITUDE hold was lifted in March 2026. Enrollment resumed.

Jones Trading upgraded to Buy with a $29 target after the holds lifted. Bank of America raised its target to $19 and bumped its probability of success estimate from 38% to 55%. The stock jumped 14.2% on the news of the clinical hold being lifted.

But the nex-z saga is a reminder: editing DNA inside a living person carries real risks. The edits are permanent. There's no undo button.

The Competitive Landscape Just Got Interesting

Right now, HAE patients rely on chronic treatments they take forever. For transthyretin amyloidosis, the standard of care includes TTR stabilizers like tafamidis (Vyndamax) and TTR silencers like Alnylam's vutrisiran (Amvuttra), which patients receive every three months via injection.

Intellia's pitch to patients and payers is straightforward: why take a drug every few weeks or months for the rest of your life when one infusion could solve the problem permanently? It's the Netflix-versus-cable argument of medicine. Pay once, get the whole library.

Of course, "pay once" in gene therapy often means a staggering upfront price tag. But the health economics math tends to favor one-time cures over decades of chronic therapy, especially for payers thinking long-term.

What This Means for the CRISPR Revolution

Casgevy's approval in 2023 proved CRISPR could work as medicine. But it was limited by the ex vivo model: only blood disorders, only at specialized centers, only with brutal chemotherapy prep.

Intellia's in vivo approach cracks open the door to everything else. Liver diseases. Heart conditions. Neurological disorders. Any tissue a lipid nanoparticle can reach becomes a potential target. There are currently more than 150 CRISPR trials running across the industry, and Intellia's regulatory submission could set the template for all of them.

If the FDA accepts the filing, reviews the data favorably, and approves lonvo-z, it won't just be a win for Intellia. It'll validate an entire therapeutic modality. It's the difference between proving one airplane can fly and proving that flight itself is commercially viable.

The Bottom Line

Intellia is attempting something no company has done before: getting an in vivo CRISPR therapy across the FDA finish line. The Phase 2 data were extraordinary. The Phase 3 readout just dropped. The filing timeline is set.

But between here and approval, there are safety reviews, manufacturing questions, and pricing debates waiting in the wings. The nex-z clinical hold showed that even promising programs can stumble when you're rewriting human DNA in real time.

Still, if this works? We're looking at a fundamental shift in how we treat genetic disease. Not managing symptoms. Not silencing genes temporarily. Actually fixing them, permanently, with a single dose.

The CRISPR revolution started in a lab. It's about to walk into a pharmacy.

The Kidney Drug That Wasn't Supposed to Get Approved

Filspari just became the first FDA-approved treatment for FSGS, a rare kidney disease that's been without an approved therapy forever. The twist? The pivotal trial technically missed its main goal. How Travere pulled off the approval anyway is a story worth reading.